Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …

Importance The androgen receptor (AR) pathway is emerging as a potential therapeutic
target in breast cancer. To date, AR-targeted drugs have been approved only for treatment of …

Background The androgen receptor (AR) is a pivotal drug target for the treatment of prostate
cancer, including its lethal castration-resistant (CRPC) form. All current non-steroidal AR …

Nuclear receptors (NRs) are transcription factors actively involved in many aspects of human
physiology and pathology, serving as sensors of stimuli, master regulators of downstream …

Sex steroids are major promoters of the growth of breast and prostate cancers. This Review
by Poutanen et al. describes the development of treatments for these cancer types that act to …

Despite the initial efficacy of androgen deprivation in prostate cancer, virtually all patients
progress to castration-resistant prostate cancer (CRPC). Androgen receptor (AR) signaling …

Today much is known about cytochrome P450 (P450) enzymes and their catalytic specificity,
but the range of reactions catalyzed by each still continues to surprise. Historically, P450s …

Triple-negative breast cancer (TNBC) is an aggressive disease with outcomes inferior to
those of other breast cancer subtypes. No targeted therapies are currently approved for …

Castration and androgen receptor (AR) pathway inhibitors induce profound and sustained
responses in advanced prostate cancer. However, the inevitable recurrence is associated …

Castration resistant prostate cancer (CRPC) remains androgen dependant despite castrate
levels of circulating testosterone following androgen deprivation therapy, the first line of …